Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities (Q35791924)

10 August 2017

1 reference

title

Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities (English)

1 reference

10 August 2017

1 reference

Robert S Rosenson

1

1 reference

PubMed ID

15177118

10 August 2017

language of work or name

1 reference

1 March 2004

1 reference

10 August 2017

1 reference

10 August 2017

173

1 reference

10 August 2017

1-12

1 reference

10 August 2017

1

1 reference

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stress?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12 000 men and women from The Copenhagen City Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Oxidant stress in the vasculature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

The oxidative modification hypothesis of atherosclerosis: does it hold for humans?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Oxidized LDL and thickness of carotid intima-media are associated with coronary atherosclerosis in middle-aged men: lower levels of oxidized LDL with statin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Lesioned low density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Oxidative modifications of LDL increase its binding to extracellular matrix from human aortic intima: influence of lesion development, lipoprotein lipase and calcium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Minimally modified low density lipoprotein stimulates monocyte endothelial interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Oxidized lipoproteins influence gene expression by causing oxidative stress and activating the transcription factor NF-kappa B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Oxidized LDL-induced NF-kappa B activation and subsequent expression of proinflammatory genes are defective in monocyte-derived macrophages from CD36-deficient patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Macrophage scavenger receptor class A: A multifunctional receptor in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Oxidized low-density lipoprotein induces the production of interleukin-8 by endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Vasoprotection by nitric oxide: mechanisms and therapeutic potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Extent of oxidative modification of low density lipoprotein determines the degree of cytotoxicity to human coronary artery cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Inhibition of LOX-1 by statins may relate to upregulation of eNOS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Lipoprotein atherogenicity: an overview of current mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Lipid compositional differences of small, dense low-density lipoprotein particle influence its oxidative susceptibility: possible implication of increased risk of coronary artery disease in subjects with phenotype B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Novel physiological function of sphingomyelin in plasma. Inhibition of lipid peroxidation in low density lipoproteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Core lipid structure is a major determinant of the oxidative resistance of low density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Oxidative susceptibility of low density lipoprotein subfractions is related to their ubiquinol-10 and alpha-tocopherol content

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Activation of NADPH oxidase required for macrophage-mediated oxidation of low-density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

A central role for the endothelial NADPH oxidase in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

12/15-lipoxygenase, oxidative modification of LDL and atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Iron and LDL-oxidation in atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

A critical overview of the chemistry of copper-dependent low density lipoprotein oxidation: roles of lipid hydroperoxides, alpha-tocopherol, thiols, and ceruloplasmin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Mechanisms of the pro- and anti-oxidant actions of nitric oxide in atherosclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

The simultaneous generation of superoxide and nitric oxide can initiate lipid peroxidation in human low density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Antioxidant effects of nitric oxide and nitric oxide donor compounds on low-density lipoprotein oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Nitric oxide inhibition of lipoxygenase-dependent liposome and low-density lipoprotein oxidation: termination of radical chain propagation reactions and formation of nitrogen-containing oxidized lipid derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

The formation of some antigenic epitopes in oxidized human low-density lipoprotein is inhibited by nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Cardiovascular morbidity and mortality associated with the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Correlates of markers of oxidative status in the general population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non-diabetic subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Hypertriglyceridemia, insulin resistance, and the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Serum vitamin C concentrations and diabetes: findings from the Third National Health and Nutrition Examination Survey, 1988-1994.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Mechanisms underlying endothelial dysfunction in diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Dietary antioxidants preserve endothelium-dependent vessel relaxation in cholesterol-fed rabbits.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Vitamin E reverses cholesterol-induced endothelial dysfunction in the rabbit coronary circulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Chronic vitamin E treatment prevents defective endothelium-dependent relaxation in diabetic rat aorta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atheroscleros

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N'-diphenyl-phenylenediamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Relation of vascular oxidative stress, alpha-tocopherol, and hypercholesterolemia to early atherosclerosis in hamsters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. II. Cellular composition and proliferation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Effect of vitamin E on endothelial vasodilator function in patients with hypercholesterolemia, chronic smoking or both.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Improvement of endothelial vasomotor dysfunction by treatment with alpha-tocopherol in patients with high remnant lipoproteins levels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Vitamin C intake and mortality among a sample of the United States population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Vitamin E consumption and the risk of coronary heart disease in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Vitamin E consumption and the risk of coronary disease in women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Vitamin C deficiency and risk of myocardial infarction: prospective population study of men from eastern Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Dietary antioxidants and carotid artery wall thickness. The ARIC Study. Atherosclerosis Risk in Communities Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Vitamin E supplementation and cardiovascular events in high-risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Effect of diet and exercise intervention on blood pressure, insulin, oxidative stress, and nitric oxide availability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Cellular antioxidant effects of atorvastatin in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Non-lipid-lowering effects of statins on atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

HMG-CoA Reductase Inhibitors Decrease CD11b Expression and CD11b-Dependent Adhesion of Monocytes to Endothelium and Reduce Increased Adhesiveness of Monocytes Isolated From Patients With Hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

Current strategies and perspectives for correcting endothelial dysfunction in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900239-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0021-9150(03)00239-9

1 reference

10 August 2017

1 reference

PubMed ID

15177118